Clinical trial
Cardiovascular Risk Assessment in Patients Treated With Caduet
NCT00297973 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00297973 |
|---|---|
| Title | Cardiovascular Risk Assessment in Patients Treated With Caduet |
| Official title | Cardiovascular Risk Assessment In Patients With Hypertension And At Least Three Other Risk Factors, Treated With Caduet Compared To Usual Care: The Right Study |
| Acronym | RIGHT |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Procedure |
| Interventions | Blood pressure measurements, Blood samples |
| Enrollment | 1,442 |
| Start date | Feb 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Mar 1, 2006 |
| Last update posted | Jan 27, 2021 |
| Countries | France |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: